Trial Profile

Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belimumab (Primary) ; Cyclophosphamide; Diphenhydramine; Hydroxychloroquine; Methylprednisolone; Paracetamol; Prednisone; Rituximab
Indications Lupus nephritis
Focus Adverse reactions
Acronyms CALIBRATE

Most Recent Events

15 Nov 2023 Results of a post-hoc modified intention to treat analysis assessing clinical outcomes and comparing them with BEAT-lupus trial presented at the ACR Convergence 2023
04 Aug 2020 Results published in the Arthritis and Rheumatology.
05 Apr 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com